Tacrolimus and Myocardial Hypertrophy
Overview
Affiliations
Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac wall thickening. Our findings demonstrated that tacrolimus-induced myocardial hypertrophy correlated with tacrolimus blood levels, and that myocardial hypertrophy induced by tacrolimus was reversible. However, no patients developed clinically significant symptoms related to myocardial hypertrophy.
Kaye A, Shah S, Johnson C, De Witt A, Thomassen A, Daniel C Curr Issues Mol Biol. 2025; 47(1).
PMID: 39852117 PMC: 11763814. DOI: 10.3390/cimb47010002.
Hernandez Silva G, Puerto Chaparro R, Martinez Melo J, Bueno C, Martinez Rodriguez J, Trillos S Clin Case Rep. 2022; 10(11):e6539.
PMID: 36397856 PMC: 9664538. DOI: 10.1002/ccr3.6539.
Cardiovascular effects of immunosuppression agents.
Elezaby A, Dexheimer R, Sallam K Front Cardiovasc Med. 2022; 9:981838.
PMID: 36211586 PMC: 9534182. DOI: 10.3389/fcvm.2022.981838.
Kanazawa K, Iwai-Takano M, Kimura S, Ohira T J Med Ultrason (2001). 2019; 47(1):97-105.
PMID: 31792638 DOI: 10.1007/s10396-019-00990-y.
Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Prytula A, van Gelder T Pediatr Nephrol. 2018; 34(1):31-43.
PMID: 29479631 DOI: 10.1007/s00467-018-3892-8.